AUG 7 2026
ITM Isotope Technologies Munich SE — 177Lu-edotreotide
for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
About
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are cancers that start in the stomach, intestines, or pancreas and often produce hormones that cause disruptive symptoms. ITM-11 is a targeted radiation therapy where a tumor-seeking molecule delivers a radioactive particle directly to the cancer cells. This focused delivery of radiation could offer a way to treat these slow-growing but difficult tumors.
Pivotal trial
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on 177Lu-edotreotide
- FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs - Targeted Oncology
- FDA Issues CRL to 177Lu-Edotreotide for GEP-NETs - OncLive
- ITM Says FDA Issues Complete Response Letter For 177Lu-Edotreotide (ITM-11) NDA - tradingview.com
- 177Lu-edotreotide Improves HRQOL vs Everolimus in GEP-NETs - CancerNetwork
- Dr Strosberg on Survival Outcomes With 177Lu-edotreotide in Select SSTR+ GEP-NET Subgroups - OncLive